Abeona Therapeutics, Inc
11
1
2
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
27.3%
3 terminated/withdrawn out of 11 trials
62.5%
-24.0% vs industry average
36%
4 trials in Phase 3/4
40%
2 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH
Role: collaborator
A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients
Role: lead
A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB
Role: lead
Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa
Role: lead
Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease
Role: collaborator
Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Role: lead
A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101
Role: lead
Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB
Role: lead
MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers
Role: lead
MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers
Role: lead
A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail
Role: lead
All 11 trials loaded